Anixa Biosciences Inc revenue

Anixa Biosciences Inc's revenue was $210,000 in fiscal 2024, up 0.0% on the year before. Since fiscal 2010 ($730,675) it has grown at a compound -9.9% a year.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Anixa Biosciences Inc: revenue history, annual
Fiscal year	2010Oct 2010	2011Oct 2011	2012Oct 2012	2013Oct 2013	2014Oct 2014	2015Oct 2015	2016Oct 2016	2017Oct 2017	2018Oct 2018	2019Oct 2019	2021Oct 2021	2023Oct 2023	2024Oct 2024
Revenue	731	1,003	940	389	3,667	9,255	300	363	1,113	250	512	210	210
Growth on the year before	—	+37.3%	−6.3%	−58.6%	+843.1%	+152.4%	−96.8%	+20.8%	+206.9%	−77.5%	+104.8%	−59.0%	0.0%

US$ thousands unless shown otherwise. Fiscal quarters.

Anixa Biosciences Inc: revenue history, quarterly
Quarter	2021 Q2Apr 2021	2021 Q3Jul 2021	2021 Q4Oct 2021	2022 Q1Jan 2022	2022 Q2Apr 2022	2023 Q2Apr 2023	2023 Q3Jul 2023	2023 Q4Oct 2023
Revenue	1	0	−1	513	0	210	0	0
Growth on the same quarter a year before	—	—	—	—	−100.0%	—	—	−100.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Anixa Biosciences Inc	$512,000	-58.9%	-28.4%
Cardiff Oncology, Inc.	$508,000	-7.0%	7.2%
Cervomed Inc.	$331,295	-95.7%	-52.7%
Medicinova Inc	$920,481	875.7%	—
Shattuck Labs, Inc.	$1.0m	-66.6%	5.2%
Longeveron Inc.	$1.2m	-42.7%	10.4%

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Anixa Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Anixa Biosciences Inc.